ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01614899
Recruitment Status : Completed
First Posted : June 8, 2012
Last Update Posted : July 1, 2015
Sponsor:
Information provided by (Responsible Party):
Sumitomo Dainippon Pharma Co., Ltd.

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : November 2014
  Study Completion Date : No date given

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 July 20, 2017
December 15, 2017
2 December 22, 2017